<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Immunol</journal-id><journal-id journal-id-type="iso-abbrev">J. Immunol</journal-id><journal-id journal-id-type="pmc-domain-id">1937</journal-id><journal-id journal-id-type="pmc-domain">jimmunol</journal-id><journal-id journal-id-type="publisher-id">JI</journal-id><journal-title-group><journal-title>The Journal of Immunology Author Choice</journal-title></journal-title-group><issn pub-type="ppub">0022-1767</issn><issn pub-type="epub">1550-6606</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>J Immunol</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC6500888</article-id><article-id pub-id-type="pmcid-ver">PMC6500888.1</article-id><article-id pub-id-type="pmcaid">6500888</article-id><article-id pub-id-type="pmcaiid">6500888</article-id><article-id pub-id-type="pmid">30988116</article-id><article-id pub-id-type="doi">10.4049/jimmunol.1800583</article-id><article-id pub-id-type="publisher-id">ji_1800583</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Autoimmunity</subject></subj-group></article-categories><title-group><article-title>Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6717-9656</contrib-id><name name-style="western"><surname>Haselmayer</surname><given-names initials="P">Philipp</given-names></name><xref ref-type="aff" rid="aff1">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Camps</surname><given-names initials="M">Montserrat</given-names></name><xref ref-type="aff" rid="aff2">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Liu-Bujalski</surname><given-names initials="L">Lesley</given-names></name><xref ref-type="aff" rid="aff3">&#8225;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nguyen</surname><given-names initials="N">Ngan</given-names></name><xref ref-type="aff" rid="aff3">&#8225;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Morandi</surname><given-names initials="F">Federica</given-names></name><xref ref-type="aff" rid="aff4">&#167;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Head</surname><given-names initials="J">Jared</given-names></name><xref ref-type="aff" rid="aff4">&#167;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>O&#8217;Mahony</surname><given-names initials="A">Alison</given-names></name><xref ref-type="aff" rid="aff5">&#182;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zimmerli</surname><given-names initials="SC">Simone C.</given-names></name><xref ref-type="aff" rid="aff6">&#8214;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bruns</surname><given-names initials="L">Lisa</given-names></name><xref ref-type="aff" rid="aff1">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bender</surname><given-names initials="AT">Andrew T.</given-names></name><xref ref-type="aff" rid="aff6">&#8214;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schroeder</surname><given-names initials="P">Patricia</given-names></name><xref ref-type="aff" rid="aff7">#</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9974-6782</contrib-id><name name-style="western"><surname>Grenningloh</surname><given-names initials="R">Roland</given-names></name><xref ref-type="aff" rid="aff6">&#8214;</xref></contrib><aff id="aff1"><label>*</label>Translational Innovation Platform Immunology, Merck KGaA, Darmstadt 64293, Germany;</aff><aff id="aff2"><label>&#8224;</label>Immunology, Merck Serono, 1201 Geneva, Switzerland;</aff><aff id="aff3"><label>&#8225;</label>Medicinal Chemistry, EMD Serono Research and Development Institute, Billerica, MA 01821;</aff><aff id="aff4"><label>&#167;</label>Molecular Pharmacology, EMD Serono Research and Development Institute, Billerica, MA 01821;</aff><aff id="aff5"><label>&#182;</label>Eurofins DiscoverX Corporation, South San Francisco, CA 94080;</aff><aff id="aff6"><label>&#8214;</label>Translational Innovation Platform Immunology, EMD Serono Research and Development Institute, Billerica, MA 01821; and</aff><aff id="aff7"><label>#</label>Translational Pharmacology, EMD Serono Research and Development Institute, Billerica, MA 01821</aff></contrib-group><author-notes><fn fn-type="con"><p>All authors were involved in the conception and design of the studies and the preparation of the manuscript. The final version was approved by all authors.</p></fn><corresp id="cor1">Address correspondence and reprint requests to Dr. Roland Grenningloh, EMD Serono Research and Development Institute, Inc., 45A Middlesex Turnpike, Billerica, MA 01821. E-mail address: <email>roland.grenningloh@emdserono.com</email></corresp></author-notes><pub-date pub-type="ppub"><day>15</day><month>5</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>15</day><month>4</month><year>2019</year></pub-date><volume>202</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">334195</issue-id><fpage>2888</fpage><lpage>2906</lpage><history><date date-type="received"><day>01</day><month>5</month><year>2018</year></date><date date-type="accepted"><day>14</day><month>3</month><year>2019</year></date></history><pub-history><event event-type="pmc-release"><date><day>15</day><month>04</month><year>2019</year></date></event><event event-type="pmc-live"><date><day>08</day><month>05</month><year>2019</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2019-05-09 00:19:57.160"><day>09</day><month>05</month><year>2019</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2019 by The American Association of Immunologists, Inc.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Copyright &#169; 2019 by The American Association of Immunologists, Inc.</copyright-holder><license license-type="open-access"><license-p>This article is distributed under The American Association of Immunologists, Inc., <underline><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.jimmunol.org/info/authorchoice">Reuse Terms and Conditions for Author Choice articles</ext-link></underline>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ji1800583.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:role="icon" xlink:href="ji1800583_thumb.gif"/><abstract abstract-type="executive-summary"><title>Key Points</title><p><list list-type="bullet" id="L1"><list-item><p>The covalent BTK inhibitor evobrutinib blocks B cell and myeloid cell activation.</p></list-item><list-item><p>Evobrutinib is efficacious in mouse models for RA, SLE, and cutaneous anaphylaxis.</p></list-item><list-item><p>Covalent binding allows modeling the relationship between BTK occupancy and efficacy.</p></list-item></list></p></abstract><abstract><p>Because of its role in mediating both B cell and Fc receptor signaling, Bruton&#8217;s tyrosine kinase (BTK) is a promising target for the treatment of autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Evobrutinib is a novel, highly selective, irreversible BTK inhibitor that potently inhibits BCR- and Fc receptor<bold>&#8211;</bold>mediated signaling and, thus, subsequent activation and function of human B cells and innate immune cells such as monocytes and basophils. We evaluated evobrutinib in preclinical models of RA and SLE and characterized the relationship between BTK occupancy and inhibition of disease activity. In mouse models of RA and SLE, orally administered evobrutinib displayed robust efficacy, as demonstrated by reduction of disease severity and histological damage. In the SLE model, evobrutinib inhibited B cell activation, reduced autoantibody production and plasma cell numbers, and normalized B and T cell subsets. In the RA model, efficacy was achieved despite failure to reduce autoantibodies. Pharmacokinetic/pharmacodynamic modeling showed that mean BTK occupancy in blood cells of 80% was linked to near-complete disease inhibition in both RA and SLE mouse models. In addition, evobrutinib inhibited mast cell activation in a passive cutaneous anaphylaxis model. Thus, evobrutinib achieves efficacy by acting both on B cells and innate immune cells. Taken together, our data show that evobrutinib is a promising molecule for the chronic treatment of B cell<bold>&#8211;</bold>driven autoimmune disorders.</p></abstract><abstract abstract-type="graphical"><title>Visual Abstract</title><p><fig id="absf1" orientation="portrait" position="float"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="gra1" position="float" orientation="portrait" xlink:href="ji1800583absf1.jpg"/></fig></p></abstract><counts><fig-count count="13"/><table-count count="0"/><equation-count count="3"/><ref-count count="79"/><page-count count="19"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>